Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

Eikon Therapeutics reports 2025 financial results and clinical pipeline progress

Eikon Therapeutics (NASDAQ:EIKN), a clinical-stage biotechnology company focused on developing novel medicines through advanced imaging and machine learning platforms, reported corporate and clinical updates on March 30, 2026, alongside its full-year 2025 financial results.

Leia mais: Eikon Therapeutics reports 2025 financial results and clinical pipeline progress
Grafa
Energy

Soluna Holdings reports revenue growth in Q4 2025 driven by Dorothy 2 expansion

Soluna Holdings (NASDAQ:SLNH), a specialized developer of green data centers for intensive computing applications such as Bitcoin mining and artificial intelligence, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

Leia mais: Soluna Holdings reports revenue growth in Q4 2025 driven by Dorothy 2 expansion
Grafa
Energy

Terrestrial Energy strengthens US footprint with site selection and $292M capital raise

Terrestrial Energy (NASDAQ:IMSR), a developer of Generation IV advanced nuclear technology, today announced its financial results and program milestones for the fourth quarter and full year ended December 31, 2025.

Leia mais: Terrestrial Energy strengthens US footprint with site selection and $292M capital raise
Grafa
Mining

USA Rare Earth bolsters balance sheet with $1.5B injection as US magnet production scales

USA Rare Earth (NASDAQ:USAR) reported a transformative shift in its financial position and operational footprint for the full year 2025, underpinned by a massive capital injection that establishes the company as a primary contender in the race to build a non-Chinese permanent magnet supply chain.

Leia mais: USA Rare Earth bolsters balance sheet with $1.5B injection as US magnet production scales
Grafa
Health

Connect Biopharma reports positive Phase 1 rademikibart data

Connect Biopharma Holdings (NASDAQ:CNTB), a clinical-stage biopharmaceutical company focused on chronic inflammatory diseases, today reported positive topline preliminary results from its Phase 1 clinical pharmacology study (CBP-201-105) evaluating an intravenous (IV) formulation of rademikibart.

Leia mais: Connect Biopharma reports positive Phase 1 rademikibart data
Grafa

United Therapeutics reports "unprecedented" Phase 3 success for Tyvaso in idiopathic pulmonary fibrosis

United Therapeutics (NASDAQ:UTHR), a public benefit corporation, today announced that its pivotal TETON-1 study evaluating nebulized Tyvaso® (treprostinil) for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint.

Leia mais: United Therapeutics reports "unprecedented" Phase 3 success for Tyvaso in idiopathic pulmonary fibrosis